Myelosuppression (thrombocytopenia, neutropenia, anemia, and febrile neutropenia) is easily the most frequent explanation for INQOVI dose reduction or interruption, taking place in 36% of people. Everlasting discontinuation because of myelosuppression (febrile neutropenia) transpired in one% of patients. Myelosuppression and worsening neutropenia may well come about more usually in th... https://fyodord230yrb9.wikicommunications.com/user